Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Chemoradiation for Esophageal Squamous Cell Carcinoma
NCT03278626Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Jun 2017
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by NYU Langone Health. Primary endpoints: Number of Unacceptable Toxicity (UT) Events at 92 days and Number of Subjects Who Achieved Clinical Complete Response (cCR) or Pathological Complete Response (pCR). Started Jun 2017; status: terminated.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03278626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278626.